Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

- CAPACITY shows potential for pirfenidone role in treatment of patients with IPF -

- Ground-breaking data from INFORM-1 study; first all-oral combination in HCV -

- Strong data from 14-day triple combination study of ITMN-191 in HCV -

BRISBANE, Calif., April 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the first quarter ended March 31, 2009. InterMune reported a net loss for the first quarter of 2009 of $42.0 million, or $1.03 per share, compared with a net loss of $29.1 million, or $0.75 per share, in the first quarter of 2008.

Dan Welch, Chairman, President and Chief Executive Officer of InterMune, said, "The first months of 2009 were an exceptionally productive period for InterMune. We began the year by reporting strong data from our triple combination study of ITMN-191 (R7227) in hepatitis C virus (HCV) patients and shortly thereafter reported results from our Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF). In April, we reported with Roche and Pharmasset exciting new data from INFORM-1, the first-ever combination of a nucleoside polymerase inhibitor and protease inhibitor in the absence of interferon in patients infected with HCV. We also recently strengthened our balance sheet by raising $63 million in cash and by exchanging $32 million in convertible debt for shares of our common stock. The remainder of 2009 is expected to be as productive for pirfenidone and ITMN-191 and we look forward to sharing those results as they develop."

InterMune reported total revenue in the first quarter of 2009 of $6.9 million, compared with total revenue of $9.3 million in the first quarter of 2008. Total revenue in the first quarter of 2009 primarily consisted of Actimmune(R) (in
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... today announces the firm brokered a long-term lease totaling 202,492 ... company, at Two Ledgemont Center in Lexington, Massachusetts ... and Brian Cohen , senior vice president, represented Shire ... Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The laboratory ... that has witnessed a number of technological advancements due ... regulatory requirements, growing need to integrate healthcare systems, and ... ease challenges in system integration. Key players in the ...
(Date:1/22/2015)... OH (PRWEB) January 22, 2015 Crystal Diagnostics ... today that it has received AOAC-PTM Certifications for the six ... O121, and O145; collectively referred to as STEC or the ... 1 colony forming unit (cfu) per 325 g of raw ...
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 23D Motion Capture Just Got Easy 2
... 4 , - Microplasmin Shows Clear Promise ... Achieving Macular Hole Closure and Traction Release,Without Need ... a biotechnology company,focused on vascular and eye diseases, ... IIT trial at the American Society of Retina ...
... Calif., Dec. 3 BioMarin,Pharmaceutical Inc. (Nasdaq and ... have initiated a program to develop an IgA ... shown to cleave IgA,complexes, the deposition of which ... treatment alternatives. BioMarin has executed a research,and option ...
... FRANCISCO, Dec. 3 /PRNewswire/ - Wall Street closed out ... week of November with gains, it,still posted a 4% ... its,biggest percentage gain in four and a half years ... prices and the,weakness in the economy," said G. Steven ...
Cached Biology Technology:ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting 2ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting 3ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting 4BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease 2BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease 3BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease 4Biotech Survives Market Turbulence in November 2Biotech Survives Market Turbulence in November 3Biotech Survives Market Turbulence in November 4Biotech Survives Market Turbulence in November 5
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. One major ... multimodal biometric systems. Multimodal biometric systems utilize more than ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center today ... School of Medicine. Funding for this $50 million capital project ... publicly launched next summer. The medical education ... Reynolds Tobacco Company complex, adjacent to 525@vine in Wake Forest ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... has been successful in gaining major European Union ... of biological samples, such as DNA, can be ... Europe. The Centre for Integrated Genomic Medical ... Medicine, is playing a key role in developing ...
... of researchers led by a first-year UC Davis faculty member ... should lead to far more accurate predictions of global climate ... online Wednesday (June 18) by the journal Nature . ... nitrogen cycle in temperate and tropical forests. Defying laws of ...
... a marine creature led by scientists at Scripps Institution of ... a key area of the tree of life. Linda ... from the United States, Europe and Asia, have deciphered and ... small, worm-like marine animal called amphioxus, also known as a ...
Cached Biology News:Manchester clears first hurdle in €170 million biobank building boom 2UC Davis researcher leads climate-change discovery 2Worm-like marine animal providing 2Worm-like marine animal providing 3
Rabbit anti-Junctophilin-4 (C-term)...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
... / Mount is the standard water based ... especially for the permanent preservation of peroxidase ... is easy to use and exhibits excellent ... first aqueous mounting medium that permits the ...
... antibody development to targets including proteins and ... and cancer-specific surface antigens. A&Gs service ... completed in approximately 40 days (duration may ... antigens). Phase I: Immunization, test bleed ...
Biology Products: